IDH-889 is primarily investigated for its potential therapeutic applications in cancer treatment, particularly in cancers associated with mutations in the IDH1 and IDH2 genes. These mutations are commonly found in certain types of gliomas, acute myeloid leukemia (AML), and cholangiocarcinoma. By targeting the mutated IDH enzymes, IDH-889 works to inhibit the production of the oncometabolite 2-hydroxyglutarate (2-HG), which is known to drive tumor growth and progression. This mechanism helps restore normal cellular differentiation and reduces the proliferation of cancer cells. Its application is being explored in clinical trials to evaluate its efficacy and safety as a targeted therapy for patients with IDH-mutant cancers.